cardiology Archives -

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it

BMS builds case for mavacamten label ahead of FDA decision

https://pharmaphorum.com/news/bms-builds-case-for-mavacamten-label-ahead-of-fda-decision/

News/ News/ R&D

FDA fast tracks Bayer’s oral anticoagulant asundexian

Phil Taylor anticoagulant, asundexian, Bayer, Bristol-Myers Squibb, cardiology, Johnson & Johnson, milvexian, stroke 0 Comment

The FDA has granted fast-track status to Bayer’s oral Factor Xia inhibitor asundexian, which is in phase 2

FDA fast tracks Bayer’s oral anticoagulant asundexian

https://pharmaphorum.com/news/fda-fast-tracks-bayers-oral-anticoagulant-asundexian/

Market Access/ News/ News

Jardiance gets parity with Farxiga in US as FDA clears use in heart failure

Phil Taylor AstraZeneca, Boehringer Ingelheim, cardiology, Eli Lilly, Farxiga, fda, heart failure, Jardiance, regulatory approval 0 Comment

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with

Jardiance gets parity with Farxiga in US as FDA clears use in heart failure

https://pharmaphorum.com/news/jardiance-gets-parity-with-farxiga-in-us-as-fda-clears-use-in-heart-failure/

Digital/ News/ News

Abbott bags FDA okay for AI-based heart imaging software

Phil Taylor Abbott, artificial intelligence, cardiology, digital, digital health, fda, imaging 0 Comment

The FDA has approved an artificial intelligence-based imaging software developed by Abbott that is used to help physicians

Abbott bags FDA okay for AI-based heart imaging software

https://pharmaphorum.com/news/abbott-bags-fda-okay-for-ai-based-heart-imaging-software/

News/ News/ R&D

Look out BMS, Cytokinetics has its eye on mavacamten’s turf

Phil Taylor Bristol-Myers Squibb, cardiology, Cytokinetics, hypertrophic cardiomyopathy, mavacamten, Myokardia 0 Comment

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM)

Look out BMS, Cytokinetics has its eye on mavacamten’s turf

https://pharmaphorum.com/news/look-out-bms-cytokinetics-has-its-eye-on-mavacamtens-turf/

News/ News/ R&D

First US patient gets total heart replacement with CARMAT device

Phil Taylor artificial heart, cardiology, CARMAT, heart failure, medical device 0 Comment

An experimental artificial heart developed by French medical device specialist CARMAT has been implanted into the first of

First US patient gets total heart replacement with CARMAT device

https://pharmaphorum.com/news/first-us-patient-gets-total-heart-replacement-with-carmat-device/

Market Access/ News/ News

Novartis tries to rescue stalled inclisiran filing with FDA

Phil Taylor Alnylam, cardiology, cholesterol, fda, inclisiran, Novartis 0 Comment

Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on

Novartis tries to rescue stalled inclisiran filing with FDA

https://pharmaphorum.com/news/novartis-tries-to-rescue-stalled-inclisiran-filing-with-fda/

News/ News/ Sales and Marketing

Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance

Phil Taylor AstraZeneca, Boehringer Ingelheim, cardiology, Eli Lilly, Farxiga, heart failure, Jardiance 0 Comment

AstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will

Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance

https://pharmaphorum.com/news/farxiga-faces-first-heart-failure-rival-as-eu-oks-boehringer-lillys-jardiance/

News/ News/ R&D

Novo Nordisk crowns cell therapy pipeline with $598m Heartseed deal

Phil Taylor cardiology, heart failure, Heartseed, Japan, Novo Nordisk, Regenerative medicine, stem cell therapy 0 Comment

Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed

Novo Nordisk crowns cell therapy pipeline with $598m Heartseed deal

https://pharmaphorum.com/news/novo-nordisk-crowns-cell-therapy-pipeline-with-598m-heartseed-deal/

Trending

cardiology

Login